Effect of Acarbose in Treatment of Type II Diabetes Mellitus: A Double-blind, Crossover, Placebo-controlled Trial

This study evaluated the efficacy of acarbose in improvement of metabolic control in patients with fairly, well controlled non-insulin-dependent diabetes mellitus (NIDDM). Fifteen patients with mean age and duration of diabetes of 57.5±2.6 (SE) and 7.5±1.5 years, respectively were recruited and completed our study protocol. This study was a double-blind, crossover, placebo-controlled design consisting of two twelve-week treatments of acarbose and placebo separated by an eight-week washout period. Acarbose was effective in lowering of 1-hour and 2-hour postprandial plasma glucose from 251.7±10.7 and 205.3±9.1 mg/dl to 197.4±7.0 (p= 0.001) and 181.5±8.5 mg/dl (p=0.03), respectively. Fasting plasma glucose was slightly decreased but without significant change, from 150.8±7.3 to 140.8±6.1 mg/dl (p=0.07). Overall glycemic control tended to improve during the study period as indicated by the falling of HbAlc levels from 7.7±0.4 to 7.0±0.2 per cent (p=0.05). Serum C-peptide both fasting and post-prandial as well as serum lipids were not affected by acarbose. Almost half of the patients treated with acarbose had mild and tolerable gastrointestinal adverse effects. In conclusion, acarbose, as combined therapy with other oral hypoglycemic agents, was effective in improvement of glycemic control particularly postprandial hyperglycemia in fairly, well controlled NIDDM patients with mild and acceptable adverse effects.